Dr. Owen Witte, director of UCLA’s Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is a 2014 inductee into the American Association for Cancer Research (AACR) Academy.

Witte’s research laid the foundation for the development of the drug Imatinib (Gleevec®), the first targeted therapy for chronic myeloid leukemia.

“Our 2014 class of fellows includes a number of the most prestigious laboratory researchers and physician-scientists who have contributed enormously to the cancer field,” said Dr. Margaret Forti, chief executive officer of the AACR.

The Academy was created to recognize and honor distinguished scientists whose important research has significantly advanced the fight against cancer. The fellows of the Academy are selected by a rigorous peer-review process that evaluates them based on their scientific achievements in cancer research.